Curis

Curis is a clinical-stage oncology biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor being studied in combination with ibrutinib in hematologic malignancies (including the TakeAim CLL and TakeAim Lymphoma studies) and as a monotherapy in solid tumors. The company has historically worked on multiple first-in-class targeted cancer therapeutics in partnership with major pharma. Curis completed a 1-for-5 to 1-for-25 reverse stock split effective in July 2026 to maintain Nasdaq listing compliance, with split-adjusted trading beginning shortly thereafter.